These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. Lü M; Yu S; Deng J; Yan Q; Yang C; Xia G; Zhou X PLoS One; 2016; 11(10):e0163743. PubMed ID: 27723762 [TBL] [Abstract][Full Text] [Related]
4. Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis. Rokkas T; Ekmektzoglou K; Graham DY Helicobacter; 2023 Feb; 28(1):e12936. PubMed ID: 36458328 [TBL] [Abstract][Full Text] [Related]
5. Empirical Li M; Wang X; Meng W; Dai Y; Wang W Therap Adv Gastroenterol; 2023; 16():17562848231196357. PubMed ID: 37667805 [TBL] [Abstract][Full Text] [Related]
6. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966 [TBL] [Abstract][Full Text] [Related]
7. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022 [TBL] [Abstract][Full Text] [Related]
8. Noninvasive molecular analysis of Ierardi E; Giorgio F; Iannone A; Losurdo G; Principi M; Barone M; Pisani A; Di Leo A World J Gastroenterol; 2017 Apr; 23(14):2453-2458. PubMed ID: 28465629 [TBL] [Abstract][Full Text] [Related]
9. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of Zhang M; Chen CY; Wang XT; Lyu B Zhonghua Nei Ke Za Zhi; 2017 May; 56(5):368-374. PubMed ID: 28460509 [No Abstract] [Full Text] [Related]
10. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405 [TBL] [Abstract][Full Text] [Related]
11. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Chen Q; Long X; Ji Y; Liang X; Li D; Gao H; Xu B; Liu M; Chen Y; Sun Y; Zhao Y; Xu G; Song Y; Yu L; Zhang W; Liu W; Graham DY; Lu H Aliment Pharmacol Ther; 2019 Jun; 49(11):1385-1394. PubMed ID: 31020673 [TBL] [Abstract][Full Text] [Related]
12. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326 [TBL] [Abstract][Full Text] [Related]
13. Tailored therapy for Ma Q; Li H; Liao J; Cai Z; Zhang B Front Pharmacol; 2022; 13():908202. PubMed ID: 36160444 [No Abstract] [Full Text] [Related]
14. Tailored eradication Choi YI; Chung JW; Park DK; Kim KO; Kwon KA; Kim YJ; Seo JY World J Gastroenterol; 2019 Dec; 25(46):6743-6751. PubMed ID: 31857776 [TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis. Kale-Pradhan PB; Mihaescu A; Wilhelm SM Pharmacotherapy; 2015 Aug; 35(8):719-30. PubMed ID: 26173786 [TBL] [Abstract][Full Text] [Related]
16. Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis. Gingold-Belfer R; Niv Y; Schmilovitz-Weiss H; Levi Z; Boltin D J Gastroenterol Hepatol; 2021 Oct; 36(10):2649-2658. PubMed ID: 34114673 [TBL] [Abstract][Full Text] [Related]
17. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Wenzhen Y; Yumin L; Quanlin G; Kehu Y; Lei J; Donghai W; Lijuan Y Intern Med; 2010; 49(12):1103-9. PubMed ID: 20558925 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice. Shaikh T; Fallone CA Can J Gastroenterol Hepatol; 2016; 2016():7321574. PubMed ID: 27446864 [TBL] [Abstract][Full Text] [Related]
19. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. Buzás GM; Józan J J Gastroenterol Hepatol; 2007 Oct; 22(10):1571-81. PubMed ID: 17845685 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P Digestion; 2013; 88(1):33-45. PubMed ID: 23880479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]